Teclison - Combating Cancer by Addressing Insufficient Anti-Cancer Immunity
Teclison has pioneered an innovative method to combat all solid tumors by addressing the issue of insufficient anti-cancer immunity in patients with solid tumors. They developed a three-pronged approach to harness patients’ own immunity to fight against cancer. The lead product candidate achieved an efficacy of >50% response and abscopal effect in immunotherapy-refractory hepatocellular carcinoma. Teclison has been very capital efficient by spending only $30 million to advance its lead asset TEC-001 to phase 2 and achieves sufficient efficacy to apply for Breakthrough Therapy Designation from FDA, and to develop an immunotherapy platform applicable to all solid tumors.
Their distinctive tumor-targeting strategy not only surpasses traditional chemotherapy but also leverages the body's natural immune processes to awaken and enhance the patient's immune response against tumors. Post-treatment, patients have a remarkable increase in anti-tumor cells (by over 100 folds), which can attack any remaining cancer cells. These anti-tumor cells can be further activated and boost the effectiveness of anti-PD-(L)1 immune checkpoint inhibitors.
This approach has advanced to phase 2 clinical trials and demonstrated a robust response and remote tumor-killing effect (abscopal effect) in cancer patients who had previously not responded to immunotherapy. Teclison’s pipeline product candidates include TATE (Trans-arterial TEC-001 Embolization) and THIANA (Tumor Hypoxia-Inducing and Necrotizing Agent) and can be applicable in all solid tumors to have a broad market.
Additionally, the expanded anti-tumor immune cells offer a cost-effective opportunity for direct isolation and ex vivo expansion (TACI or Tumor-Activated Cellular Immunity), presenting a novel form of cell therapy that can be manufactured with a simple and affordable process without a need of genetic modification. This new TACI cell therapy is applicable to all solid tumors with multiple advantages, including simple manufacture from PBMCs, polyclonal nature in targeting multiple tumor antigens to avoid resistance, and low toxicity in sparing patients from the intense chemotherapy for lymphodepletion in other types of cell therapy.
Teclison website: www.teclison.com